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INTRODUCTION
Extended-spectrum  -lactamases (ESBLs) produced by
Gram-negative bacilli have been a serious problem in hospi-
talized patients worldwide (1). These enzymes are most com-
monly produced by strains of Klebsiella pneumoniae, one of the
important nosocomial respiratory pathogens. ESBLs have been
very prevalent in Korea most being of the types, SHV-12,
SHV-2a, and TEM-52, however, CTX-M types have emerg-
ed recently as well (2, 3). ESBLs do not hydrolyze cephamy-
cins, however, the cephamycin-hydrolyzing plasmid-medi-
ated AmpC  -lactamase (PABL), CMY-1, emerged in Korea
in 1988 (4). As well, various types of PABLs have been increa-
singly detected in intrinsically cephamycin-susceptible Gram-
negative bacilli in other parts of the world (5, 6). In 2003,
36% and 37% of K. pneumoniae isolates at a Korean tertiary-
care hospital showed resistance to ceftazidime and cefoxitin,
respectively (unpublished data). These results suggest a high
prevalence of ESBL and PABL-producing isolates. Recent in-
creases of K. pneumoniae isolates concomitantly producing PABL
and ESBL pose a serious therapeutic problem as carbapenems
remain the only active  -lactams against these organisms (7).
This study was conducted to determine the prevalence and
the types of ESBLs and PABLs among K. pneumoniae isolates
from respiratory specimens. This information is crucial for con-
trolling of the spread of resistance and for the decision of em-
pirical selection of antimicrobial agents.
MATERIALS AND METHODS
Clinical isolates and antimicrobial susceptibility testing
A total of 373 non-duplicate isolates of K. pneumoniae, ex-
cluding scant growth, were isolated from the lower respirato-
ry specimens of patients in a Korean tertiary-care hospital in
Seoul over a one year period starting in September 2002. The
isolates were identified by the conventional methods (8) or by
using the Vitek GNI card (bioMerieux, Marcy I’Etoile, France).
Antimicrobial susceptibility was tested by the National
Committee for Clinical Laboratory Standards (NCCLS) disk
diffusion method (9). ESBL production was detected with the
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Respiratory isolates of Klebsiella pneumoniae in Korea during 2002-2003 were stu-
died to determine the prevalence and types of extended-spectrum  -lactamases
(ESBLs) and plasmid-mediated AmpC  -lactamases (PABLs). ESBL-production
was tested by double-disk synergy, and genotypes of  -lactamases were determined
by PCR and sequencing. ESBLs were detected in 28.4% of 373 isolates, and the
most prevalent types were SHV-12 (63 isolates) and CTX-M-14 (9 isolates). Forty
of 75 ESBL-producers (53.5%) also had PABLs: 21 isolates with CMY-2-like, 17 with
DHA-1-like. Pulsed-field gel electrophoresis showed 19 types and 25 of 74 isolates
had an identical pattern, indicating nosocomial spread. Dissemination of ESBL- and
PABL-producing K. pneumoniae strains in Korea is a particular concern, as it limits
the choice of antimicrobial agents for treatment of infections.
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double-disk synergy test with cefotaxime, ceftazidime, aztre-
onam, cefepime, and amoxicillin/clavulanic acid disks, or phe-
notypic confirmatory tests as recommended by the NCCLS
(9).
MICs of  -lactams were determined by the NCCLS agar
dilution method (9). Antimicrobial agents used were cepha-
lothin and cefepime (Sigma, St. Louis, MO, U.S.A.), ceftazi-
dime and clavulanic acid (GlaxoSmithKline, Greenford, U.K.),
cefotaxime (Aventis, Frankfurt, Germany), cefoxitin and imi-
penem (Merck/Sharp & Dohme, Rahway, NJ, U.S.A.), and
aztreonam (Bristol-Myers Squibb, Princeton, NJ, U.S.A.). 
Isoelectric focusing and resistance transfer
Isoelectric focusing was carried out following the manufac-
turer’s instructions using pre-cast gels with pH gradient 3-10,
and a ThermoFlow Electrophoresis Temperature Control Sys-
tem (Novex Experimental Technologies, San Diego, CA,
U.S.A.). Resistance transfer was tested by an agar mating me-
thod with nalidixic acid-resistant recipient E. coli RG 176,
rifampicin-resistant E. coli RG 488, or azide-resistant E. coli
J53. Mueller-Hinton agar containing 100 mg/L of nalidixic
acid, rifampicin or azide, and 2 mg/L of ceftriaxone or aztre-
onam was used to select transconjugants.
Molecular methods
PCR for the detection of blaTEM and blaSHV in the transcon-
jugants was carried out as described previously (10). PCR for
the detection of blaCTX-M in ESBL-producing clinical isolates
was performed with primers CTXUNI-F (5′ -CVATGTGCA
GYACCAGTAA-3′ ) and CTXUNI-R (5′ -ARGTSACCAG
AAYMAGCGG-3′ ). A thermocycler (Eppendorf, Hamburg,
Germany) was used under the following conditions: 94℃for
5 min, 35 cycles of 94℃for 30 sec, 55℃for 30 sec, and 72℃
for 45 sec, followed by 72℃for 7 min. PCR for detection of
family-specific PABL gene alleles in cefoxitin-intermediate
or -resistant isolates was performed by the method of Perez-
Perez and Hanson with slight modification (11). PCR for de-
tection of blaDHA in DHA PCR positive isolates was performed
using the forward primer DHA1-F (5′ -TCTGCCGCTGAT
AATG TCG-3′ ) for detection of blaDHA-1 and blaDHA-2; reverse
primers were DHA1-R (5′ -GCCGCCGGATCATTCAGCG
C-3′ ) and DHA2-R (5′ -TCTGCCGGGTCATTCAACAT-
3′ ), respectively.
Sequencing was performed using the following primers:
for blaCTX-M, CTXM-F (5′ -AAAAATGATTGAAAGGTGG
TTGT-3′ ) and CTXM-R (5′ -TTACAGCCCTTCGGCGAT
GA-3′ ); for blaCMY-1, CMY1E-F (5′ -TATTAGAGCGGTTTA
GGCTG-3′ ) and CMY1E-R (5′ -AATGTACCGCCCTCTT
TC-3′ ); for blaCMY-2, CITS-F (5′ -AACACACTGATTGCGTC
TGA-3′ ) and CITS-R (5′ -TCCTGGGCCTCATCGTCAGT
TAT-3′ ). Sequencing of blaTEM, blaSHV, and blaDHA was perform-
ed with the primers as described previously (10, 11). DNAs
in the PCR products were extracted with a gel extraction kit
(Qiagen, Hilden, Germany) and used for direct sequencing
of ESBL and PABL genes. Both strands were analyzed by the
dideoxy-chain termination method with an ABI 3700 Auto-
sequencer (Perkin-Elmer, Foster City, CA, U.S.A.).
Genomic DNA from K. pneumoniae isolates was digested
using XbaI (Takara, Japan) and separated using a CHEF-DRII
system according to the manufacturer’s instruction (Bio-Rad,
Hercules, CA, U.S.A.). The pulsed-field gel electrophoresis
(PFGE) band patterns were analyzed with the computer soft-
ware UVIBand Map V.99 (UVItec Ltd., Cambridge, U.K.) by
the un-weighted pair group method using arithmetic averages
(UPGMA).
RESULTS
Among the 373 K. pneumoniae isolates, 106 (28.4%) tested
positive using either the double-disk synergy test or NCCLS
confirmatory test, indicating ESBL production. Resistance was
transferable in 75 (70.8%) of the isolates. Seventy-six ESBL
genes were detected by PCR in 75 transconjugants (Table 1).
The most common ESBL type, SHV-12, was identified in
26 of 63 blaSHV allele-positive isolates, which showed  -lacta-
mase bands with a pI of 8.2. The second most common type
was CTX-M-14, being detected in nine isolates. SHV-2a and
TEM-52 were identified in only one and two isolates, respec-
tively.
Forty of 75 (53.3%) clinical isolates with ESBL genes had
PABLs. Twenty one contained blaCMY-2-like, 17 contained bla
DHA-1-like, and two contained blaCMY-1 (Table 1). Antibiotic re-
sistance by disk diffusion method of isolates without ESBL
and PABL genes, those with ESBL genes, and those with both
ESBL and PABL genes were: to cefoxitin 6%, 3%, and 100%;
to aminoglycosides 5-9%, 40-97%, and 90-100%; and to lev-
ofloxacin 4%, 60%, and 80%, respectively.
The MIC90s of  -lactams to ESBL-producers were: cefota-
xime and ceftazidime for both PABL-nonproducer and -produ-
cers 64 mg/L and >128 mg/L, respectively; cefotaxime/clavu-
*The number of isolates with their AmpC genes sequenced is shown in
parenthesis.
ESBL type
(No. of isolates)
SHV-12 (26) 13 1 (1)* 3 (2) 9 (0)
SHV-12-like (37) 15 1 (1) 16 (2) 5 (2)
SHV-2a (1) 1 0 0 0
TEM-52 (2) 2 0 0 0
CTX-M-14 (8) 3 0 2 (0) 3 (0)
CTX-M-14+SHV-12 (1) 1 0 0 0
Total (75) 35 2 (2) 21 (4) 17 (2)
Table 1. Plasmid-mediated AmpC- -lactamases detected from
extended-spectrum -lactamase-producing  K. pneumoniae iso-
lates
No. of isolates with AmpC  -lactamase
None CMY-1 CMY-2 DHA-1lanate and ceftazidime/clavulanate for PABL-nonproducer 2
mg/L and 0.25 mg/L, respectively, and PABL-producer 32 mg/
L and 128 mg/L, respectively; cefoxitin for PABL-nonproducer
and -producer 16 mg/L and >128 mg/L, respectively (Table 2).
PFGE of XbaI-digested genomic DNA of 74 ESBL produc-
ers showed 19 types including nine subtypes. Twenty-five iso-
lates gave an identical pattern, O1 (Fig. 1), which was mostly
isolated from NCU patients. Among these, 18 isolates produ-
ced both SHV-12-like and CMY-2-like enzymes.
DISCUSSION
The prevalence of ESBLs among clinical isolates varies de-
pending on countries and institutions. In the United States
occurrence of ESBL production in Enterobacteriaceae ranges
from 0 to 25%, with the national average being around 3%
(1). ESBL production among K. pneumoniae isolates was com-
paratively higher in Taiwan and Hong Kong, 8.5% and 13%,
respectively, but very low in Japan, less than 1% (1). The pre-
valence in our study during 2002-2003 was 28.4%, which
is significantly higher than the United States, Taiwan, or Hong
Kong, but still similar to that of other Korean study (10).
SHV-12, TEM-52, and SHV-2a were common in the late
1990s in Korea when compared to other countries (2). In this
study, SHV-12-like enzyme remained prevalent (64 of 75),
however SHV-2a and TEM-52 were found in only one and
two isolates, respectively.
Recently, strains with CTX-M type ESBLs have been increa-
singly isolated from many parts of the world (1). In Korea, a
few strains harboring CTX-M-14  -lactamase have been re-
ported since 2000 (3, 10). In this study, nine of 106 isolates
harbored CTX-M-14 type ESBLs, indicating a gradual increase
of this type.
Since 1989 over 20 types of PABLs have been reported world-
wide (6). In 1995, CMY-1b was reported in Korea with a one
amino acid change, Asn346Ile, compared to CMY-1 (5). It
was later renamed CMY-10 (12). This type was however not
detected in this study; neither was CMY-11 which was first
identified in E. coli in 2002 in Korea (13).
Korean Antimicrobial Surveillances showed that the cefoxi-
tin-resistance rate of K. pneumoniae increased from 14% in 1998
to 20% in 2001 (14), suggesting dissemination of PABL-pro-
ducing isolates. In this study, 41 of 75 (54.7%) isolates were
cefoxitin resistance, and 40 isolates had PABL genes. Isolates
with blaCMY-2-like and blaDHA-1-like were detected in 21 and 17 iso-
lates respectively, while blaCMY-1 was found in only two isolates.
CMY-2 (BIL-1, LAT-2) was first identified in K. pneumoniae
isolates from Greece in 1990 (15). CMY-2 was the most preva-
lent and most geographically distributed PABL, with reports
from Africa, Europe, India, Taiwan, and the United States (6).
It is a concern that as is ACT-1 enzyme, CMY-2 together with
reduced permeability can render the isolate resistant even to
imipenem (16, 17).
DHA-1, an inducible PABL, which was first identified in
Salmonella enteritidis isolated in Saudi Arabia in 1992, has been
reported in several other countries including Korea (18, 19).
DHA-1-producing K. pneumoniae isolates were reported to be
especially prevalent in a Korean university hospital (20).
ESBL or PABL-producing strains were often resistant to
aminoglycosides and fluoroquinolones, too. In our study, iso-
lates with both ESBLs and PABLs, were more often resistant
to cefoxitin, aminoglycosides, and levofloxacin.
The MIC90s of cefotaxime and ceftazidime for ESBL-pro-
ducing strains were similar to those for strains producing both
ESBLs and PABLs. Addition of clavulanic acid cefotaxime and
ESBLs and AmpC  -lactamases in K. pneumoniae isolates 963
ESBL-producing
strains (No. of isolates)
MIC (mg/L) Susceptibility (%)
Range 50% 90% Susceptible Intermechiate Resistant
PABL-production Cephalothin >128 >128 >128 0 0 100
positive (40) Ceftazidime 4->128 >128 >128 5.0 0 95.0
Ceftazidime/clavulanate 0.5->128 128 128 - - -
Cefotaxime 4->128 16 64 12.5 67.5 20.0
Cefotaxime/clavulanate 0.12-64 16 32 - - -
Cefoxitin 16->128 >128 >128 0 7.5 92.5
Cefepime 0.5-128 2 8 92.5 0 7.5
Aztreonam 16-128 64 64 0 2.5 97.5
Imipenem 0.12-8 0.25 0.5 97.5 2.5 0
PABL-production Cephalothin >128 >128 >128 0 0 100
negative (35) Ceftazidime 4->128 128 >128 5.7 0 96.3
Ceftazidime/clavulanate 0.5-2 1 2 - - -
Cefotaxime 8->128 16 64 17.1 62.9 20.0
Cefotaxime/clavulanate 0.03-0.5 0.12 0.25 - - -
Cefoxitin 2-16 8 16 71.4 28.6 0
Cefepime 1-32 4 16 88.6 2.9 8.6
Aztreonam 8-128 64 128 2.9 14.2 82.9
Imipenem 0.12-1 0.12 0.5 100 0 0
Table 2. Antimicrobial susceptibilities of ESBL-producing K. pneumoniae isolates with and without concomitant production of PABLs
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ceftazidime reduced the MIC90s for ESBL producers, but not
for strains producing both ESBLs and PABLs.
In this study, PFGE of XbaI-digested genomic DNA sho-
wed that many isolates had the patterns O (29 isolates) and
M (13 isolates). Some isolates with different ESBLs, or both
ESBLs and PABLs, showed a few identical patterns, imply-
ing that both clonal and horizontal spread, and the propensi-
ty of K. pneumoniae to acquire resistance genes, has a role for
their high prevalence in this study.
In conclusion, SHV-12 type ESBL-producing K. pneumoni-
ae are increasing among lower respiratory isolates. As well, it
seems that CTX-M-14-producing isolates are emerging in Ko-
rea. It also seems that the coexistence of PABLs such as CMY-
2 and DHA-1 is common. Spreading of ESBL-producing st-
rains with PABL genes is a concern, as it causes limitations
in the selection of antimicrobial agents for optimal treatment
of patients.
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